StockNews.com assumed coverage on shares of Inuvo (NYSE:INUV – Free Report) in a research note released on Wednesday morning. The brokerage issued a hold rating on the stock.
Separately, LADENBURG THALM/SH SH started coverage on Inuvo in a research report on Tuesday, April 2nd. They set a buy rating and a $1.00 price target on the stock.
View Our Latest Analysis on Inuvo
Inuvo Stock Performance
Inuvo (NYSE:INUV – Get Free Report) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter. The firm had revenue of $17.02 million for the quarter. Inuvo had a negative net margin of 11.46% and a negative return on equity of 51.44%. On average, research analysts forecast that Inuvo will post -0.01 EPS for the current fiscal year.
Institutional Investors Weigh In On Inuvo
Large investors have recently added to or reduced their stakes in the stock. Procyon Advisors LLC increased its position in Inuvo by 121.8% in the fourth quarter. Procyon Advisors LLC now owns 61,600 shares of the company’s stock worth $26,000 after buying an additional 33,827 shares during the period. Vanguard Group Inc. increased its position in Inuvo by 0.8% in the first quarter. Vanguard Group Inc. now owns 5,495,657 shares of the company’s stock worth $1,874,000 after buying an additional 46,290 shares during the period. Finally, Perkins Capital Management Inc. grew its stake in shares of Inuvo by 11.9% in the fourth quarter. Perkins Capital Management Inc. now owns 7,043,457 shares of the company’s stock worth $2,993,000 after purchasing an additional 749,250 shares in the last quarter. 29.36% of the stock is owned by institutional investors and hedge funds.
About Inuvo
Inuvo, Inc engages in the advertising technology and services business primarily in the United States. It sells information technology solutions to brands, agencies, and large consolidators of advertising demand (platforms). Its platforms optimize the purchase and placement of advertising in real time.
See Also
- Five stocks we like better than Inuvo
- Health Care Stocks Explained: Why You Might Want to Invest
- AbbVie Stock: A Perfect Dip for Investors to Buy
- Insider Trading – What You Need to Know
- Forget NVIDIA: Super Micro Computer Stock Leads in Momentum
- What is the Dogs of the Dow Strategy? Overview and Examples
- GitLab Stock Rebounds: The Inside Story of Its Comeback
Receive News & Ratings for Inuvo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inuvo and related companies with MarketBeat.com's FREE daily email newsletter.